Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

67.88 +0.02 (+0.03%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Kymera Therapeutics Stock Is Gaining Wednesday ↗
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell... 
Via Benzinga
News headline image
Analyst Ratings for Kymera Therapeutics ↗
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying ↗
Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
Executives Buy Around $141M Of 4 Stocks ↗
Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher ↗
U.S. stocks traded slightly higher toward the end of trading on Tuesday. 
Via Benzinga
News headline image
Why Kymera Therapeutics Shares Are Falling Today ↗
 
Via Benzinga
News headline image
Kymera Therapeutics: Q1 Earnings Insights ↗
Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
81 Biggest Movers From Yesterday ↗
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
News headline image
Analyst Ratings for Kymera Therapeutics ↗
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
80 Biggest Movers From Yesterday ↗
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to... 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday. 
Via Benzinga
News headline image
41 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET ↗
Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474 ↗
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022 ↗
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... 
Via Benzinga
News headline image
Kymera Discloses New Development Cancer Program ↗
Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
News headline image
Where Kymera Therapeutics Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ: 
Via Benzinga
News headline image
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More ↗
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
News headline image
Kymera Prices $223M Equity Offering At $47/Share ↗
Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.